- Home
- INKT vs NRXP Comparison
INKT vs NRXP Comparison
Compare INKT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- NRXP
- Stock Information
- Founded
- INKT 2017
- NRXP 2015
- Country
- INKT United States
- NRXP United States
- Employees
- INKT N/A
- NRXP N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- NRXP Health Care
- Exchange
- INKT Nasdaq
- NRXP Nasdaq
- Market Cap
- INKT 28.8M
- NRXP 32.6M
- IPO Year
- INKT 2021
- NRXP N/A
- Fundamental
- Price
- INKT $40.61
- NRXP $3.21
- Analyst Decision
- INKT Buy
- NRXP Strong Buy
- Analyst Count
- INKT 3
- NRXP 4
- Target Price
- INKT $37.50
- NRXP $28.50
- AVG Volume (30 Days)
- INKT 2.6M
- NRXP 202.4K
- Earning Date
- INKT 08-12-2025
- NRXP 08-13-2025
- Dividend Yield
- INKT N/A
- NRXP N/A
- EPS Growth
- INKT N/A
- NRXP N/A
- EPS
- INKT N/A
- NRXP N/A
- Revenue
- INKT N/A
- NRXP N/A
- Revenue This Year
- INKT N/A
- NRXP N/A
- Revenue Next Year
- INKT N/A
- NRXP N/A
- P/E Ratio
- INKT N/A
- NRXP N/A
- Revenue Growth
- INKT N/A
- NRXP N/A
- 52 Week Low
- INKT $4.56
- NRXP $1.10
- 52 Week High
- INKT $76.00
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- INKT 68.63
- NRXP 51.07
- Support Level
- INKT $6.80
- NRXP $3.12
- Resistance Level
- INKT $76.00
- NRXP $3.53
- Average True Range (ATR)
- INKT 5.71
- NRXP 0.18
- MACD
- INKT 4.21
- NRXP -0.05
- Stochastic Oscillator
- INKT 48.86
- NRXP 41.82
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.